Department of Allergy and Immunology, College of Medicine, College of Nursing, University of South Florida, 601 5th Street South, St Petersburg, FL 33701, USA.
Division of Allergy and Immunology, Department of Pediatrics, Children's Research Institute, University of South Florida, Johns Hopkins All Children's Hospital, 140 7th Avenue South, CRI 4008, St Petersburg, FL 33701, USA.
Immunol Allergy Clin North Am. 2020 Aug;40(3):527-537. doi: 10.1016/j.iac.2020.04.002. Epub 2020 Jun 9.
Immunoglobulin replacement therapy is standard of care in treatment of many primary immunodeficiency diseases. The goal of replacement therapy is to reduce infections in individuals with primary immune deficiency and improve their quality of life. Immunoglobulin replacement therapy is most often lifelong, therefore ease of administration is vital for adherence to treatment. Self-infusion via subcutaneous intravenous immunoglobulin (SCIG) allows patient input to design an individualized and optimal treatment plan. Because SCIG regimens are flexible and allow for increased autonomy, patients receiving SCIG report improved quality of life. This article summarizes the dosing, administration, and adverse event management of SCIG infusions.
免疫球蛋白替代疗法是许多原发性免疫缺陷病治疗的标准方法。替代疗法的目的是减少原发性免疫缺陷个体的感染，提高其生活质量。免疫球蛋白替代疗法通常是终身的，因此给药的便利性对于治疗的依从性至关重要。通过皮下静脉注射免疫球蛋白（SCIG）进行自我输注可以让患者参与设计个体化和最佳的治疗方案。由于 SCIG 方案具有灵活性并允许更大的自主权，因此接受 SCIG 的患者报告生活质量得到改善。本文总结了 SCIG 输注的剂量、给药和不良反应管理。
